All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Investigators Focus on Reducing On-Target, Off-Tumor Toxicities With CAR T-Cell Therapy in Solid Tumors

March 14th 2025

Renier Brentjens, MD, PhD, details solid tumors his laboratory is investigating CAR T-cell therapy in and ways to mitigate on-target, off-tumor toxicities.

Acalabrutinib Plus Venetoclax and Obinutuzumab Displays High Level of Activity in First-Line High-Risk CLL

March 13th 2025

Acalabrutinib with venetoclax and obinutuzumab was effective and well tolerated in treatment-naive CLL harboring a TP53 aberration.

Nadofaragene Firadenovec May Propel Advances in Intermediate-Risk NMIBC Management

March 13th 2025

Neal D. Shore, MD, FACS, discusses the evaluation of nadofaragene firadenovec in intermediate-risk NMIBC and its potential effect on treatment strategies.

Fixed-Duration Mosunetuzumab Demonstrates Preliminary Activity in BTK Inhibitor–Exposed R/R MCL

March 13th 2025

Single-agent mosunetuzumab generated response rates in patients with relapsed/refractory MCL who previously received a BTK inhibitor.

Roswell Park’s Intensive Care Unit Earns National Recognition for Exceptional Patient Outcomes

March 13th 2025

Roswell Park Comprehensive Cancer Center’s Intensive Care Unit has earned the Beacon Award for Excellence from the AACN.

BLA Accepted in China for Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer

March 13th 2025

A BLA has been accepted in China seeking the approval of tisotumab vedotin for metastatic cervical cancer that has progressed on or after systemic therapy.

177Lu rhPSMA-10.1 Injection Generates Favorable Radiation Dosimetry Data in mCRPC

March 13th 2025

177Lu rhPSMA-10.1 injection led to proportionally higher absorbed radiation doses in tumors vs healthy tissues in patients with mCRPC.

Palbociclib/Letrozole Combo Boosts PFS in ER+ Advanced/Recurrent Endometrial Cancer

March 13th 2025

Palbociclib plus letrozole prolonged PFS compared with placebo plus letrozole in patients with ER-positive advanced endometrial cancer.

Navtemadlin Will Be Evaluated as Add-On Therapy to Ruxolitinib in Myelofibrosis

March 13th 2025

The POIESIS trial is evaluating navtemadlin plus ruxolitinib in JAK inhibitor–naive patients with myelofibrosis with a suboptimal response to ruxolitinib.

Casdatifan Monotherapy Shows Early Efficacy Signals and Tolerable Safety Profile in Pretreated ccRCC

March 12th 2025

Treatment with casdatifan was well tolerated and showed meaningful clinical activity in patients with previously treated ccRCC.

Investigators Are Making Headway Bringing CAR T-Cell Therapy to Solid Tumors

March 12th 2025

Renier Brentjens, MD, PhD, details 3 reasons it’s challenging to make CAR T-cell therapies applicable for solid tumors and ways to overcome the obstacles.

FDA Grants Orphan Drug Designation to Rhenium (186Re) Obisbemeda for Leptomeningeal Metastases in Lung Cancer

March 12th 2025

The FDA granted orphan drug designation to rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases from lung cancer.

Fox Chase Cancer Center’s Biosample Repository Receives Reaccreditation From College of American Pathologists

March 12th 2025

Fox Chase Cancer Center’s Biosample Repository Facility was recently awarded reaccreditation by the College of American Pathologists based on the results of an on-site inspection.

Maintenance OSE2101 Plus FOLFIRI Meets Primary OS End Point in Advanced/Metastatic PDAC

March 12th 2025

Maintenance treatment with OSE2101 plus FOLFIRI after FOLFIRINOX induction chemotherapy displayed positive topline results in advanced/metastatic PDAC.

Imetelstat Earns EU Approval for Transfusion-Dependent Anemia in Lower-Risk MDS

March 12th 2025

The European Commission has approved imetelstat for the treatment of patients with transfusion-dependent anemia in lower-risk myelodysplastic syndrome.

Anti-CD38-CAR-γδ T Cells Show Preclinical Cytotoxicity in Myeloma

March 12th 2025

Preclinical cytotoxicity was demonstrated with anti-CD38-CAR-gamma-delta T cells in multiple myeloma.

HCP Survey Outlines Challenges, Strategies for Venetoclax Initiation in CLL in the Community Setting

March 12th 2025

John M. Burke, MD, discusses identified challenges in the initiation of venetoclax in patients with CLL within a community-based setting.

INB-100 Following HSCT Displays Long-Lasting Activity in Pretreated AML

March 12th 2025

The γδ T-cell agent INB-100 demonstrated a 100% relapse-free survival rate in patients with AML.

BOVen Regimen Is Safe and Effective in First-Line TP53-Mutated MCL

March 11th 2025

BOVen met the primary end point of 2-year PFS in a phase 2 study, displaying high response rates in treatment-naive TP53-mutated MCL.

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

March 11th 2025

MT-8421, a novel engineered toxin body targeting CTLA-4, was not associated with grade 4 or 5 toxicities in patients with select advanced solid tumors.